Ads
related to: eye disease- No Prescription Needed
Rx-Strength Allergy Eye Relief
From Common Allergens.
- Beat The Allergy Season
Pataday Offers Relief From Common
Eye Allergens. Learn More Today.
- No Prescription Needed
Search results
5 Fun Ways to Stay Fit With Your Partner—Without Going to the Gym
Woman's Day· 6 hours agoStaying physically fit doesn’t require a gym membership, and it doesn’t have to be a solitary...
Eye Disease-Focused Glaukos' 'Investor Interest Should Continue To Gain Momentum:' Analyst - Glaukos...
Benzinga· 6 days agoThursday, Glaukos Corporation GKOS reported a first-quarter adjusted EPS loss of $(0.70), up from...
Health Benefits of Astaxanthin
Health via Yahoo News· 3 days agoMay Help Improve Symptoms of Dry Eye Research shows that oral supplementation of astaxanthin may help improve mild-to-moderate symptoms of dry eye ...
Is Wegovy or Ozempic Better for Weight Loss?
MediaFeed via AOL· 6 days agoJacob Wackerhausen/Istockphoto The most common side effects of Ozempic include: Pancreatitis (inflammation of the pancreas) Diabetic retinopathy...
Head-to-head Superiority to High-dose Dulaglutide: Innovent's First Phase 3 Clinical Trial of...
CBS 47 Fresno· 2 hours agoInnovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology ...
Ocular Therapeutix Inc Reports First Quarter 2024 Earnings
GuruFocus.com via Yahoo Finance· 1 day agoThe company, a prominent biopharmaceutical entity focused on innovative therapies for eye diseases,...
Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings: Narrowing Losses Amidst Clinical Advancements
GuruFocus.com via Yahoo Finance· 13 hours agoThe biopharmaceutical company, known for its focus on developing treatments for serious and rare...
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 7 hours agoHalozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2024 Earnings Call Transcript May 7, 2024 Halozyme...
EyePoint Pharmaceuticals Trial of Duravyu in Diabetic Eye Disease Fails to Meet Primary Endpoint
Market Watch· 3 days agoEyePoint Pharmaceuticals said that topline results from a Phase 2 clinical trial evaluating Duravyu in non-proliferative diabetic retinopathy didn't meet the pre-specified primary endpoint.
EyePoint Pharmaceuticals’ stock plunges as eye treatment fails to meet trial goal
Market Watch· 3 days agodropped nearly 30% in premarket trading Monday after the company said its experimental...
